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A BS T R AC T
BACKGROUND

Desmoid tumors (also referred to as aggressive fibromatosis) are connective tissue
neoplasms that can arise in any anatomical location and infiltrate the mesentery,
neurovascular structures, and visceral organs. There is no standard of care.
METHODS

In this double-blind, phase 3 trial, we randomly assigned 87 patients with progressive, symptomatic, or recurrent desmoid tumors to receive either sorafenib (400mg tablet once daily) or matching placebo. Crossover to the sorafenib group was
permitted for patients in the placebo group who had disease progression. The
primary end point was investigator-assessed progression-free survival; rates of
objective response and adverse events were also evaluated.

The authors’ affiliations are listed in the
Appendix. Address reprint requests to
Dr. Gounder at Memorial Sloan Kettering
Cancer Center, 300 E. 66th St., New York,
NY 10065, or at gounderm@mskcc.org.
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Copyright © 2018 Massachusetts Medical Society.

RESULTS

With a median follow-up of 27.2 months, the 2-year progression-free survival rate
was 81% (95% confidence interval [CI], 69 to 96) in the sorafenib group and 36%
(95% CI, 22 to 57) in the placebo group (hazard ratio for progression or death,
0.13; 95% CI, 0.05 to 0.31; P<0.001). Before crossover, the objective response rate
was 33% (95% CI, 20 to 48) in the sorafenib group and 20% (95% CI, 8 to 38) in
the placebo group. The median time to an objective response among patients who
had a response was 9.6 months (interquartile range, 6.6 to 16.7) in the sorafenib
group and 13.3 months (interquartile range, 11.2 to 31.1) in the placebo group.
The objective responses are ongoing. Among patients who received sorafenib, the
most frequently reported adverse events were grade 1 or 2 events of rash (73%),
fatigue (67%), hypertension (55%), and diarrhea (51%).
CONCLUSIONS

Among patients with progressive, refractory, or symptomatic desmoid tumors,
sorafenib significantly prolonged progression-free survival and induced durable
responses. (Funded by the National Cancer Institute and others; ClinicalTrials.gov
number, NCT02066181.)
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esmoid tumors (also called aggressive fibromatosis) are rare, locally aggressive neoplasms that arise from connective
tissues.1 The annual incidence of the condition is
estimated to be 1000 patients in the United
States, and the prevalence may be higher. Desmoid tumors typically affect young adults in
their 20s and 30s, but they can occur in children,
adolescents, and older adults. Most desmoid tumors are sporadic (>90%) and harbor CTNBB1
mutations; a minority of tumors are associated
with germline APC mutations and Gardner’s
syndrome.2-4 Common primary sites affected by
these tumors include the abdominal wall, mesentery, and neurovascular bundle of the extremities. Desmoid tumors do not metastasize and
pose a low risk of death (except in Gardner’s
syndrome), but they confer substantial complications. Patients may be asymptomatic or may
present with severe pain, swelling, deformity,
loss of range of motion, bowel obstruction or
perforation, or compromise of vital organs.5 Additional associated complications in young adults
include long-term opioid use, social isolation,
insomnia, anxiety, depression, and interruption
of education and employment.6
Although a number of agents have activity
against desmoid tumors, no accepted standard
of care exists for systemic treatment of the tumors.7 Beyond a few prospective trials, most relevant clinical data have been derived from case
series and retrospective analyses. Interpretation
of the data is challenging, given the unpredictable natural history of the condition. Desmoid
tumors can show rapid growth followed by periods of stabilization, spontaneous regression, or
subsequent growth phases.2 Spontaneous regression is reported in up to 20% of patients.8 An
up-front watch-and-wait strategy is increasingly
advocated for many patients.9-11 Surgery has been
the standard of care for primary treatment, but
the risk of local recurrence remains unacceptably
high (>40%). Local (radiation therapy) or systemic
treatments are usually indicated in patients who
have disease-related symptoms or progressive
disease. Systemic treatment options include hormonal blockade, cytotoxic chemotherapy, and tyrosine kinase inhibitors; the response rates associated with these treatments vary (0 to 40%).12-19
For example, in small prospective studies, imati
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nib has been found to have limited activity (6 to
11%), and no predictive biomarkers of benefit
were found.20
In a retrospective analysis, sorafenib, an oral
multitargeted receptor tyrosine kinase inhibitor,
at a starting dose of 400 mg once daily was
shown to have acceptable safety and was associated with a response rate of 25%, as evaluated
with Response Evaluation Criteria in Solid Tumors
(RECIST), version 1.1, as well as with improvements in quality of life.21 The retrospective study
also highlighted that RECIST may underestimate
efficacy and that a better criterion may be magnetic resonance imaging (MRI) T2-weighted signal intensity, an imaging biomarker that signifies a biologic transformation from a cellular
tumor to a collagenous scar.22 This hypothesis
prompted us to conduct a randomized, doubleblind, placebo-controlled, phase 3 trial to evaluate the safety and efficacy of sorafenib in the
treatment of desmoid tumors.

Me thods
Patients

We enrolled patients 18 years of age or older with
a histologically documented desmoid tumor
(aggressive fibromatosis) if they had measurable
disease and radiographic progression (of ≥10%)
in maximum unidimensional measurement within the previous 6 months, recurrent or primary
disease that was deemed inoperable or as requiring extensive surgery, or symptomatic disease.
An additional entry criterion was an absence of
previous sorafenib exposure; no minimum or
maximum number of previous systemic treatments was stipulated. The complete entry and
crossover eligibility criteria, including baseline
laboratory values, are provided in the protocol,
available with the full text of this article at
NEJM.org.
Trial Oversight

The trial was conducted in accordance with the
Declaration of Helsinki, Good Clinical Practice
guidelines, and federal and local policy on bioethics and human biologic specimens. Each participating institution obtained approval from a
local or central institutional review board. All
the patients signed informed consent forms in
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accordance with federal and institutional guidelines. The trial was designed by the first author
and monitored by the Alliance Data and Safety
Monitoring Board for the evaluation of safety
and the primary end point.
This trial was funded by the National Cancer
Institute and was conducted by the Alliance
Clinical Trials in Oncology Group and the National Clinical Trials Network (Table S1 in the
Supplementary Appendix, available at NEJM.org).
Sorafenib was provided by the National Cancer
Institute through a research collaboration with
Bayer Pharmaceuticals.
All the data were collected, subjected to
quality-assurance measures, and analyzed by the
Alliance Statistics and Data Center. Archival tumor tissue for central pathological review, biopsy
specimens (optional), and MRI scans were de
identified with regard to patient health information and, after completion of quality-assurance
measures, were sent for central pathological review and correlative studies. The authors attest
to the accuracy and completeness of the data
and for the adherence of the trial to the protocol. The first draft of the manuscript was written
by the principal investigators (the first and second authors); all the authors reviewed the manuscript. No one who is not an author contributed
to the writing of the manuscript.
Trial Design and Treatment

In this investigator-initiated, double-blind, placebocontrolled, phase 3 trial, patients were randomly
assigned (in a 2:1 ratio) to receive either sorafenib
(at a starting dose of 400 mg once daily) or placebo. Desmoid tumors were imaged by means of
computed tomography (CT) or MRI at baseline
and every 8 weeks. Efficacy was assessed at local
institutions with the use of RECIST, version 1.1.23
Administration of sorafenib or placebo continued
until disease progression, unacceptable side effects, or withdrawal of consent. At disease progression, the patients were told whether they had
been receiving sorafenib or placebo, and those
who had been receiving placebo were eligible to
cross over to the sorafenib group if they still met
the trial entry criteria. Dose interruptions (of up
to 28 days) and one dose reduction (to 200 mg
once daily) were permitted and described in the
trial protocol.

n engl j med 379;25

End Points and Assessments

The primary end point was progression-free survival, as determined by the treating physicians in
accordance with RECIST, version 1.1. This end
point was defined as the time from randomization to progressive disease (radiographic, clinical, or both) or death, and data were censored at
the most recent disease assessment. A modification of the traditional intention-to-treat principle
was used for the analysis of the primary end
point, in which patients with an incorrect histologic diagnosis were excluded. The secondary
end points were toxic effects, the rate of radiographic response, and overall survival. Ineligible
patients who received a trial agent were included
in the assessment of toxic effects, in which the
Common Terminology Criteria for Adverse Events
(CTCAE), version 4.03, were used.
At enrollment, patients were given the option of
consenting to undergo tumor biopsies and surveys
with patient-reported outcome questionnaires at
baseline and while taking the trial regimen. Exploratory end points included assessment of pain
with the use of the Brief Pain Inventory and assessment of 11 side effects with the patient-reported
outcomes version of the CTCAE (PRO-CTCAE,
version 1.0) before crossover. Exploratory imaging end points included a comparison of RECIST
measurements with total tumor volume and MRI
T2-weighted signal intensity in patients.
Statistical Analysis

We calculated that a sample of 75 patients, each
with 12 months of follow-up, would provide 90%
power at a one-sided significance level of 0.025
(with the use of a stratified log-rank test) to
detect a median progression-free survival that
was 9 months longer with sorafenib than with
placebo (with an expected median progressionfree survival of 6 months among patients receiving placebo) and a hazard ratio of 0.4 for progression or death in the sorefenib group relative
to the placebo group. Enrollment was estimated
at 4 patients per month, for an anticipated duration of 21 months to complete enrollment. The
final analysis was to occur at the time that 52
patients had had disease progression or had died.
Sorafenib was to be declared as superior with
regard to progression-free survival if the onesided P value associated with the stratified
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log‑rank test statistic was less than 0.025. A
preplanned, nonbinding futility analysis was
performed when 24 (45%) of the 52 required
events had been observed.
Kaplan–Meier methods and Cox proportionalhazards modeling were used to estimate the distributions of time-to-event variables and hazard
ratios (including confidence intervals), respectively, accounting for stratification factors.24,25
Summary statistics, frequency tables, and parametric and nonparametric statistical tests were
used, as applicable. The maximum PRO-CTCAE
score for each item during the intervention with
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accounting for baseline PRO-CTCAE score was
tabulated for each trial group, and the difference between the groups in the proportion of
patients with a score of at least 1 and, separately, with a score of at least 3 was computed
with exact 95% confidence intervals.26 All P values and confidence intervals are two-sided and
unadjusted for multiplicity. All the observed
data were included in the analysis without imputation for missing data. All the analyses were
performed with the use of SAS software, version 9.4 (SAS Institute). The data-lock date was
January 31, 2018.

87 Patients underwent randomization

37 Were assigned to receive placebo
30 Consented to provide data on
patient-reported outcomes

50 Were assigned to receive sorafenib
37 Consented to provide data on
patient-reported outcomes

1 Withdrew before initiation
of trial regimen

1 Withdrew before initiation
of trial regimen

36 Received placebo and were included
in safety analysis

49 Received sorafenib and were included
in safety analysis

1 Was found to be ineligible
after starting treatment owing
to incorrect histologic diagnosis

36 Were included in efficacy and safety
analyses
35 Were included in primary and secondary
outcome analyses
28 Were included in analysis of patientreported outcomes

49 Were included in primary and secondary
outcome analysis
36 Were included in analysis of patientreported outcomes

36 Discontinued placebo
23 Had disease progression
1 Had other, complicating
disease
1 Withdrew after starting
regimen
1 Had other reasons
10 Had trial-group assignment
unmasked

30 Discontinued sorafenib
11 Withdrew after starting
regimen
10 Had adverse events
5 Had disease progression
3 Had other reasons
1 Underwent alternative
therapy

0 Were receiving placebo at data lock

31 Were receiving sorafenib at data lock
19 Were receiving initially assigned regimen
12 Crossed over from placebo

Figure 1. Randomization and Follow-up among the Patients in the Trial.
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R e sult s
Patients, Enrollment, and Treatment

From March 21, 2014, to January 6, 2016, a total
of 87 patients were enrolled across 24 sites; 50
patients were randomly assigned to the sorafenib
group and 37 to the placebo group (Fig. 1). A
systems computer algorithm error was detected
after 70 patients (38 in the sorafenib group and
32 in the placebo group) had been enrolled. The
randomization ratio was approximately 1.6 to
1.7:1 (sorafenib:placebo) instead of the prespecified 2:1 ratio. This error was shared with the
data and safety monitoring board, institutional
review boards, treating physicians, and patients
(in October 2015), with correction for the remainder of enrollment.
The characteristics of the patients at baseline
were well balanced between the two trial groups
(Table 1).27 A larger percentage of female than
male patients were enrolled (69%), and the median age of the patients was 37 years (interquartile range, 28 to 50), findings consistent with the
natural history of desmoid tumors; 80% of the
patients reported their race as white. The median
dose of sorafenib that was administered across
the entire trial was 400 mg daily. Dose interruptions occurred in 65% of the patients in the
sorafenib group (32 of 49) and 34% of the patients in the placebo group (12 of 35), and dose
reductions due to toxic effects occurred in 31%
(15 of 49) and 11% (4 of 35), respectively. At data
cutoff, 19 patients (39%) who had initially been
assigned to the sorafenib group continued to
take the drug. At the time of the interim analysis, the data and safety monitoring board also
requested an efficacy analysis, and subsequently
the trial was halted and unblinded.
Efficacy

Of the 87 patients who underwent randomization, 84 (97%) were included in the analysis of
primary and secondary end points, with a median follow-up of 27.2 months (interquartile
range, 22.0 to 31.7) among the 83 surviving
patients. Although the median progression-free
survival has not yet been reached, the estimates
of the progression-free survival rates at 1 year
were 89% (95% confidence interval [CI], 80 to
99) in the sorafenib group and 46% (95% CI, 32
to 67) in the placebo group, and the estimates

n engl j med 379;25

at 2 years were 81% (95% CI, 69 to 96) and 36%
(95% CI, 22 to 57), respectively. The results for
progression-free survival favored sorafenib, with
an 87% lower risk of progression or death in the
sorafenib group than in the placebo group (hazard ratio for disease progression or death, 0.13;
95% CI, 0.05 to 0.31; P<0.001) (Fig. 2). Overall,
33% of the patients in the trial (28 of 84) had
disease progression: 12% of the patients (6 of 49)
in the sorafenib group and 63% of the patients
(22 of 35) in the placebo group. Clinical deterioration in the absence of radiographic evidence
was the sole indicator of progression in 11 of
the 28 patients with progression (39%; 9 patients
in the placebo group and 2 in the sorafenib
group).
The overall rate of objective response was
33% (95% CI, 20 to 48) in the sorafenib group
(16 patients [1 with a complete response and
15 with partial responses] of 49) and 20% (95%
CI, 8 to 37) in the placebo group (7 patients
[all of whom had a partial response] of 35)
(Fig. 3A, and Fig. S1 in the Supplementary Appendix). The mean best percentage change in
the sum of the target lesions (RECIST) was
−26% (range, −100 to 7) in the sorafenib group
and −12% (range, −85 to 32) in the placebo
group. The median time to a RECIST-defined
response among patients who had a response
was 9.6 months (interquartile range, 6.6 to 16.7)
in the sorafenib group and 13.3 months (interquartile range, 11.2 to 31.1) in the placebo
group (Fig. 3B). The earliest RECIST-defined
partial response occurred at 2.2 months in sora
fenib group and at 8.8 months in the placebo
group.
In the exploratory imaging analysis, 498 MRI
scans were obtained from 55 patients. We selected a training set of 11 patients who were treated
at a single institution (Memorial Sloan Kettering
Cancer Center), and we analyzed 167 MRI scans
for changes in tumor dimension (according to
RECIST) and compared this value with the
changes in total tumor volume and T2-weighted
signal intensity. As shown in Figure S2 in the
Supplementary Appendix, changes in T2-weighted
signal intensity and volumetric measurements
may be better measures of treatment effect
than RECIST. This is particularly evident when
the best response according to RECIST is stable
disease.
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Table 1. Demographic and Clinical Characteristics of the Patients at Randomization.*
Characteristic
Median age (range) — yr
Female sex — no. (%)

Placebo
(N = 37)

Sorafenib
(N = 50)

37 (21–67)

37 (18–72)

26 (70)

34 (68)

22 (59)

35 (70)

ECOG performance-status score — no. (%)†
0
1

15 (41)

15 (30)

7.6 (2.6–26.5)

8.4 (1.2–19.3)

0–2

14 (38)

17 (34)

3–6

14 (38)

21 (42)

7–10

9 (24)

12 (24)

16 (43)

16 (32)

Median sum of target lesions at randomization (range) — cm
BPI worst pain score at randomization — no. (%)‡§

Intraabdominal disease — no. (%)‡
Primary tumor site — no. (%)
Abdominal

16 (43)

14 (28)

Extraabdominal

18 (49)

32 (64)

3 (8)

4 (8)

Both abdominal and extraabdominal
Previous radiation therapy — no. (%)

3 (8)

6 (12)

Previous systemic therapy — no. (%)

15 (41)

18 (36)

Previous surgical resection — no. (%)

18 (49)

23 (46)

Newly diagnosed

19/37 (51)

26/48 (54)

Recurrent

18/37 (49)

22/48 (46)

Disease determined to be unresectable or to require surgery with
unacceptably high associated morbidity

28 (76)

44 (88)

Progression detected by radiographic imaging within 6 months
before randomization

16 (43)

19 (38)

Symptomatic disease with BPI worst pain score ≥3 and consideration
of pain narcotic introduction or escalation‖

11 (30)

16 (32)

Disease status — no./total no. (%)

Trial inclusion criteria — no. (%)¶

*	The intention-to-treat population included all patients who underwent randomization with the exception of those who
were identified after randomization as not having a desmoid tumor and those who did not initiate the trial regimen and
did not undergo further follow-up. Randomization was based on a dynamic allocation algorithm developed and implemented by the Alliance Statistics and Data Center. An error in the assignment of the trial regimen was detected and rectified after 70 patients (38 in the sorafenib group and 32 in the placebo group) had been enrolled. The program deriving
the assignments of trial regimens incorrectly recognized a patient’s crossover regimen as the initial assigned regimen
when balancing for new enrollments. Randomization was stratified according to anatomical location and level of pain
at the time of randomization, assessed with the use of the worst pain item of the Brief Pain Inventory (BPI) completed
by the patient within 28 days before randomization. There were no significant differences (P<0.05) between the groups
in any of the characteristics at the time of randomization. Percentages may not total 100 because of rounding.
†	Eastern Cooperative Oncology Group (ECOG) performance-status scores are assessed on a 5-point scale, with higher
scores indicating greater disability; a score of 5 indicates death.
‡	The characteristic was a stratification factor at randomization.
§	The BPI worst pain question was “Please rate your pain by circling the one number that best describes your pain at its
WORST in the last 24 hours: 0 (no pain)–10 (pain as bad as you can imagine).”
¶	Patients had to meet at least one of these three criteria to be eligible for participation in the trial.
‖	Consideration of pain narcotic introduction or escalation was defined as an inability to control pain with nonsteroidal
antiinflammatory drugs and consideration of the addition of narcotics or a more than 30% increase in the current use
of narcotics or the addition of a new opioid narcotic.
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Safety

Crossover

In the placebo group, 27 patients met the eligibility criteria for open-label sorafenib treatment
(20 at disease progression and 7 when the data
and safety monitoring board released results),
and 12 patients continue to take sorafenib; however, the data remain immature. The toxic effects among the patients receiving open-label
sorafenib were similar to those among the patients who were initially randomly assigned to
receive sorafenib and are listed in Table S7 in the
Supplementary Appendix.

Discussion
This randomized trial provides data on the efficacy of sorafenib in patients with progressive or
symptomatic desmoid tumors. Other agents that
are used to treat these tumors include anthracyclines (e.g., pegylated liposomal doxorubicin),
vinca alkaloids, and pazopanib. On the basis of
the predictable toxic-effects profile and substantial progression-free survival advantage conferred
by sorafenib, the drug has antitumor activity as

n engl j med 379;25

No. of No. of Median Progression-free
Patients Events
Survival (95% CI)
mo
Sorafenib
Placebo

49
35

7
22

NE (NE–NE)
11.3 (5.7–NE)

Hazard ratio for progression or death, 0.13 (95% CI, 0.05–0.31)
P<0.001

100
90

Patients without Event (%)

A total of 85 patients (49 in the sorafenib group
and 36 in the placebo group) were included in
the assessment of safety with the use of CTCAE,
version 4.0. A summary of the most common
adverse events is provided in Table 2. Adverse
events led to a significantly higher rate of discontinuation of the trial regimen in the sorafenib
group than in the placebo group (20% vs. no
patients). The most common reason for dose
reduction in the sorafenib group was skin disorders. Grade 3 adverse events that were attributed
to the trial regimen by the investigators occurred in 29% of patients in the sorafenib group
and 14% of patients in the placebo group. Grade 4
events that were associated with sorafenib included thrombocytopenia (2%) and anemia
(2%). One patient in the sorafenib group died
from disease-related bowel perforation. A list
of the side effects reported by the patients with
the use of PRO-CTCAE is provided in Table S4
and Figure S3 in the Supplementary Appendix.
The proportions of patients with nausea, diarrhea, rash, and hand–foot syndrome were higher in the sorafenib group than in the placebo
group.

Sorafenib

80
70
60
50
40

Placebo

30
20
10
0

0

3

6

9

12

15

18

21

24

27

30

33

36

22
10

17
7

14
3

8
3

4
2

3
2

Months
No. at Risk
Sorafenib
Placebo

49
35

46
28

41
20

36
18

32
15

29
12

23
11

Figure 2. Kaplan–Meier Estimates of the Duration of Progression-free Survival
at the Time of the Last Assessment.
Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, were
used by the investigators to identify disease progression. Data from patients
who did not have progression or who had died were censored and marked
by a tick. NE denotes not estimable.

first-line therapy or as subsequent therapy for
desmoid tumors.
For a locally infiltrative tumor, the prevention
of further worsening or compromise of vital
structures is a clinically meaningful end point.
In that context, among patients with progressive, symptomatic, or recurrent desmoid tumors,
the rate of progression-free survival with sora
fenib at 1 year was 89%. Patients treated with
sorafenib had an 87% lower risk of disease progression or death than those who received placebo. To balance the efficacy of the drug against the
long-term drug-related toxic effects, we chose a
starting dose of sorafenib (one 400-mg tablet
daily) that was lower than the dose used in
other types of cancer and permitted dose interruptions and reductions.5 The modest toxicity
of sorafenib was confirmed in both clinicianreported and patient-reported assessments of adverse events. Consistent with previous literature,
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A Changes from Baseline in Tumor Size
Unconfirmed response

No evaluation

Placebo

Sorafenib

Maximum Change in Tumor Size (%)

40
30
20
10
0
−10
−20
−30
−40
−50
−60
−70
−80
−90
−100

40
30
20
10
0
−10
−20
−30
−40
−50
−60
−70
−80
−90
−100

B Durations of Response
Progression

Progression
nonmeasure

Partial response

Complete response

Clinical follow-up

Continuing treatment

Sorafenib

Patient

Placebo

Death

0

6

12

18

24

30

36

0

6

Months

12

18

24

30

36

Months

Figure 3. Tumor Responses and Clinical Outcomes.
Panel A shows waterfall plots of percentage changes from baseline in tumor size as assessed by investigators according to RECIST, version 1.1. Each bar represents one patient. Horizontal dashed lines indicate the changes in tumor size that would represent a partial response (30% decrease) or progressive disease (20% increase). One patient in the sorafenib group had a complete response, defined as
total disappearance of tumor. Panel B shows swimmer plots of the duration of response and clinical outcomes among patients during
the trial. “Progression nonmeasure” denotes clinical progression without radiographic progression (20% growth). One patient in the
sorafenib group died from disease-related intestinal perforation. Duration of response was calculated as the time between the first objective response and disease progression; data from patients with ongoing responses were censored at the most recent disease assessment. Time to response during the time of the blinded trial intervention was calculated from the start of the intervention to the date of
the first objective response or to the most recent disease assessment (for patients without a response). Time to progression was the
time to disease progression or to the most recent assessment if the patient did not have disease progression.

the rates of adverse events that were based on Many of these differences were due to the ability
clinician reporting were substantially lower than to detect more lower-grade mild-to-moderate
those that were based on patient reporting.28 side effects with the use of the patient-reported
2424
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Table 2. Incidence of Adverse Events of Any Cause According to Initially Assigned Trial Regimen.*
Sorafenib
(N = 49)

Event

Grade 1 or 2

Placebo
(N = 36)

Grade 3 or 4

Grade 1 or 2

Grade 3 or 4

number of patients (percent)
Any adverse event

26 (53)

23 (47)

25 (69)

9 (25)

34 (69)

1 (2)

8 (22)

0

Events during receipt of trial regimen with incidence
≥10%†
Palmar–plantar erythrodysesthesia syndrome
Rash
Any rash or skin disorder

36 (73)

7 (14)

15 (42)

0

Papulopustular

24 (49)

6 (12)

6 (17)

0
0

Acneiform

6 (12)

0

0

Maculopapular

7 (14)

0

1 (3)

0

Skin or subcutaneous tissue disorders —
other‡

7 (14)

1 (2)

5 (14)

0

7 (14)

0

0

0

Pruritus
Fatigue

33 (67)

3 (6)

22 (61)

1 (3)

Hypertension

27 (55)

4 (8)

14 (39)

0

Diarrhea

25 (51)

0

12 (33)

0

Nausea

24 (49)

0

14 (39)

1 (3)

Myalgia

18 (37)

1 (2)

12 (33)

0

Alopecia

18 (37)

0

3 (8)

0

Arthralgia

17 (35)

1 (2)

9 (25)

0

Abdominal pain

15 (31)

1 (2)

9 (25)

4 (11)

Anorexia

15 (31)

0

9 (25)

0

Constipation

11 (22)

0

4 (11)

0

Oral mucositis

11 (22)

0

6 (17)

0

Vomiting

10 (20)

1 (2)

6 (17)

2 (6)
1 (3)

Anemia

8 (16)

1 (2)

2 (6)

Increase in alanine aminotransferase level

7 (14)

0

4 (11)

0

Decrease in platelet count

6 (12)

2 (4)

1 (3)

0
0

Hyperglycemia

6 (12)

1 (2)

3 (8)

Peripheral sensory neuropathy

6 (12)

0

1 (3)

0

Increase in aspartate aminotransferase level

5 (10)

1 (2)

3 (8)

0

Increase in blood bilirubin level

5 (10)

0

3 (8)

1 (3)

Decrease in neutrophil count

5 (10)

0

2 (6)

0

Dry skin

5 (10)

0

1 (3)

0

Headache

4 (8)

0

6 (17)

0

Decrease in white-cell count

3 (6)

0

6 (17)

0

Musculoskeletal connective-tissue disorders —
other§

3 (6)

0

4 (11)

0

*	Events that occurred while the patient was taking the initially assigned trial regimen (before crossover) are shown.
Adverse events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.
The events reported reflect the maximum severity in each category for a given patient during the treatment period; multiple occurrences of the same event in a single patient were counted once, at the highest grade at which it occurred. All
85 patients were included in the assessment of safety.
†	Events that had an incidence of 10% or higher in either trial group are shown. One patient in the sorafenib group died
from disease-related bowel perforation (not shown in this table) that was judged by the investigators not to have been
related to the drug; no other grade 5 events occurred.
‡	Events in this category included callus, swelling, plantar wart, hidradenitis supportiva, and pain.
§	Events in this category included pain and cramping.

n engl j med 379;25

nejm.org

December 20, 2018

2425

The New England Journal of Medicine
Downloaded from nejm.org at Washington University in St. Louis Becker Library on May 2, 2019. For personal use only. No other uses without permission.
Copyright © 2018 Massachusetts Medical Society. All rights reserved.

The

n e w e ng l a n d j o u r na l

PRO-CTCAE. Accordingly, we surmised that the
high rate of withdrawal from the trial due to
adverse events (20%) suggests that even greater
dose flexibility may be necessary to balance toxicity and benefit.
This trial highlights the importance of randomization in the conduct of clinical trials.
Spontaneous regression was once considered to
be anecdotal and rare (occurring in <5% of patients), but more recent retrospective, nonrandomized studies have shown higher rates of spontaneous remission.8,9 Our prospective trial, in which
desmoid tumors in patients who were taking
placebo were evaluated, provides evidence in support of an initial period of observation in patients with newly diagnosed desmoid tumors,
given that 20% of the patients in the placebo
group had disease regression. In this trial, late
responses were observed in the sorafenib group,
and response rates may increase with further
data maturation.
A final important clinical issue to note regards the feasibility and challenges of conducting clinical trials in very rare cancers. Rare
cancers are defined as those with an incidence
of less than 15 cases per 100,000 persons per
year. Although individually uncommon, rare cancers account for 25% of all cancers and are associated with poor survival.29,30 The main challenges in the design and execution of this phase 3
trial were the incidence of the cancer (0.3 cases
per 100,000 persons per year), the lack of consensus on the standard of care, the lack of predictive biomarkers for the selection of patients,
and the lack of validated, desmoid-specific patient-reported outcome measures. The unreliability of historical data on treatment and natural
history (e.g., the rate of spontaneous regression)
was an additional design challenge. All potential
trial designs (e.g., frequentist or Bayesian) should
be considered on the basis of not only their statistical properties but also their feasibility with
regard to late events or logistic support for realtime data entry. The trial conducted was an international collaboration among U.S. and Canadian
National Cancer Institutes, cooperative research
groups, patient advocacy groups, and physician
outreach groups, an endeavor that facilitated the
enrollment of 87 patients in 17 months.29,31
A limitation of this trial is that it was not
designed to directly compare the primary or
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n engl j med 379;25

of

m e dic i n e

secondary end points with meaningful improvements in pain palliation, functionality, or quality of life. The use of pain-palliation questionnaires was optional, and limited results were
available. In our exploratory analysis, we were
unable to use the Brief Pain Inventory to discern
any difference between the groups (data not
shown), contrary to previous reports. Symptoms
that affect patients with desmoid tumors are
wide-ranging, and since this trial was conducted,
a prospective, desmoid tumor–specific, patientreported outcome tool has been developed for
future trials.6 Beyond the traditional end points
that are used in clinical trials, incorporating an
evaluation of the patient experience is critical.32
The ability to use RECIST-defined responses
to correlate with treatment effect and survival
among patients with solid tumors is debated.
Data from our exploratory analysis suggested
that there is anatomical and mathematical discordance among assessments that are based on
unidimensional measurement (RECIST), tumor
volume, and T2-weighted signal intensity; therefore, RECIST — the current regulatory metric
— may underestimate treatment effects. This
phenomenon is observed in other sarcomas, such
as tenosynovial giant-cell tumors and gastrointestinal stromal tumors, in which tumor volume
and density are better predictors of treatment
effect than RECIST measurements.33,34 Similarly,
data have suggested that tumor volume or MRI
T2-weighted signal intensity — namely, a shift
from a cellular mass to a collagenous scar —
may be additional imaging biomarkers that can
potentially be used to assess treatment effects
on desmoid tumors.22,35 The appropriate duration of sorafenib treatment and its cost and
benefit relative to those of existing therapies
remain unknown. Finally, the mechanism of
action of sorafenib in desmoid tumors36 is not
known. Investigations into changes in gene
expression and protein phosphorylation of receptor tyrosine kinases (e.g., platelet-derived
growth factor receptor, fibroblast growth factor
receptor, and transforming growth factor beta
receptor) and the Wnt signaling pathway are
ongoing in the 25 sets of paired biopsy specimens we obtained.
In conclusion, in this trial, therapy with sora
fenib appeared to be effective in slowing disease
progression in patients with desmoid tumors.
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